Bain Capital Life Sciences Investors’s Cidara Therapeutics CDTX Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,020,990	Closed	-$289M	–	20
2025 Q3	$289M	Buy	3,020,990 +520,310	+21%	+$33.2M	19.2%	3
2025 Q2	$122M	Buy	2,500,680 +1,797,600	+256%	+$43.2M	15.24%	2
2025 Q1	$15.1M	Hold	703,080	–	–	2.24%	10
2024 Q4	$18.9M	Hold	703,080	–	–	2.22%	10
2024 Q3	$7.56M	Buy	+703,080	New	+$8.44M	0.79%	16

Other funds holding CDTX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Bain Capital Life Sciences Investors's CDTX Position: Q4 2025 in Review

Bain Capital Life Sciences Investors sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 3,020,990 shares — an estimated $289M sold.

Bain Capital Life Sciences Investors first reported a position in CDTX in Q3 2024 and held it in 5 quarters. The position peaked at $289M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

Bain Capital Life Sciences Investors reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 3,020,990 Cidara Therapeutics shares in Q4 2025, an estimated $289M.
Bain Capital Life Sciences Investors first reported a position in Cidara Therapeutics in Q3 2024 and held it in 5 quarters.
Bain Capital Life Sciences Investors's Cidara Therapeutics position peaked at $289M in Q3 2025.
255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2025, filed 17 Feb 2026.